1. Home
  2. DAIO vs GLTO Comparison

DAIO vs GLTO Comparison

Compare DAIO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data I/O Corporation

DAIO

Data I/O Corporation

N/A

Current Price

$3.06

Market Cap

23.4M

Sector

Industrials

ML Signal

N/A

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$30.92

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAIO
GLTO
Founded
1969
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
23.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DAIO
GLTO
Price
$3.06
$30.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.22
$36.00
AVG Volume (30 Days)
26.6K
207.8K
Earning Date
10-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,701,000.00
N/A
Revenue This Year
$9.14
N/A
Revenue Next Year
$2.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.88
$2.01
52 Week High
$3.57
$33.60

Technical Indicators

Market Signals
Indicator
DAIO
GLTO
Relative Strength Index (RSI) 56.66 70.94
Support Level $2.86 $25.60
Resistance Level $3.20 $32.20
Average True Range (ATR) 0.14 3.02
MACD 0.05 0.76
Stochastic Oscillator 74.56 92.21

Price Performance

Historical Comparison
DAIO
GLTO

About DAIO Data I/O Corporation

Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: